Contraline has appointed Dr. Yelena Tropsha to the role of chief technology officer. Dr. Tropsha brings to Contraline over 25 years of medical device experience, from front-end innovation to commercialization.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
846.4 DKK | -1.79% | -7.66% | +9.64% |
27/02 | Certain B Shares of Coloplast A/S are subject to a Lock-Up Agreement Ending on 27-FEB-2024. | CI |
14/02 | COLOPLAST : Q1 24: Many more positives beyond the margin beat |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.64% | 27.84B | |
-29.83% | 3.04B | |
-15.97% | 2.56B | |
+18.11% | 2.33B | |
+3.70% | 1.99B | |
-9.47% | 1.87B | |
-2.22% | 1.49B | |
+2.19% | 1.27B | |
+18.92% | 1.15B | |
+3.72% | 1.12B |
- Stock Market
- Equities
- COLO B Stock
- News Coloplast A/S
- Contraline Names Yelena Tropsha as CTO